Section 503A is built around a prescription for an identified individual patient. That is the architecture of the exemption, and it explains almost everything operators find confusing about holding stock.
Office use means non-patient-specific quantities, held on your shelf, administered to whoever presents. That is a different thing from a preparation made for a named person, and it is why a second category exists in the statute at all. Outsourcing facilities under § 503B were created to supply exactly this need.
So the honest frame is not “may I get compounded drugs for office use.” It is “from which kind of facility, and does my state permit it from that kind.”
The two federal categories
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Built around | A prescription for an identified patient | Production without patient-specific prescriptions |
| Office stock | Not the model the exemption describes | The model it was created for |
| Registration | State-licensed pharmacy | Registers with FDA as an outsourcing facility |
| Manufacturing standards | Not subject to cGMP under the 503A exemption | Subject to cGMP requirements |
The practical consequence is that a clinic wanting a shelf of ready-to-administer preparations is usually describing a 503B relationship, whatever its current supplier is called. Our treatment of that sourcing decision is at 503A vs 503B.
Then the states diverge, and they diverge a lot
Federal law sets the categories. Whether, and how much, a state-licensed 503A pharmacy may dispense for office use is substantially a state pharmacy board question, and the answers range from prohibition through percentage limits to comparatively permissive regimes with recordkeeping conditions.
We are not going to publish a fifty-state table here, because a per-state rule that is wrong is worse than no table. What we will say is the shape of the question you have to answer for each state you operate in:
- Does the state permit office-use dispensing from a 503A pharmacy at all?
- If it does, is there a quantity or percentage limit, and is it measured against total dispensing?
- What records must the clinic keep, and for how long?
- Is the pharmacy licensed as a nonresident pharmacy in your state, if it ships across a line?
- Does the product category carry its own rules, as controlled substances and certain biologics do?
The fifth is where weight-management and peptide programs get complicated, and it interacts with the supply history we set out at compounded GLP-1 after the shortage and the regulatory status discussion at peptide compounding status.
The failure pattern
A clinic finds a compounding pharmacy that will ship office stock, the arrangement works, and nobody asks under which state’s rules it works. Two years later the clinic has added states, the pharmacy has kept shipping, and the arrangement is being run on the assumptions of the first state.
The pharmacy’s licensure and the clinic’s permission are separate questions and both are per-state. A pharmacy lawfully shipping into one state is not evidence about another.
The second pattern is quieter. A clinic treats a box on the shelf as inventory rather than as a regulated holding, so nobody owns the lot numbers, the expiry dates or the record of what was administered to whom. Office stock removes the patient-specific paper trail that a prescription would have created, which means the clinic has to create one deliberately. Where that does not happen, the gap shows up first in a board inquiry and second in any diligence exercise, because a buyer reads inventory records as a proxy for how the rest of the operation is run.
What this means for you
Decide first whether you actually need office stock or whether patient-specific dispensing serves the program, because that choice determines which supplier category you are in and removes most of the complexity if you can live with it. If you do need stock, look hard at whether your supplier is an outsourcing facility rather than a compounding pharmacy that is willing, since the category is doing the work rather than the willingness. Then answer the five questions above for every state you serve, and write the answers down with dates, because this is the area where a working arrangement quietly becomes a non-compliant one as the footprint grows. And keep the advertising question separate: what you may hold is not what you may say, which is at what you may say about compounded semaglutide.
Related reading
Frequently asked questions
What is office-use compounding?
Obtaining compounded preparations in non-patient-specific quantities, held as stock and administered to patients who present, rather than made for an identified individual against a prescription. It is the model 503B outsourcing facilities were created to supply.
Can a 503A pharmacy supply office stock?
Section 503A is built around a prescription for an identified patient, so office stock is not the model the exemption describes. Whether a state-licensed 503A pharmacy may dispense for office use, and in what quantity, is largely a state pharmacy board question and the answers vary widely.
What is the difference between 503A and 503B for this purpose?
A 503A pharmacy compounds against prescriptions for identified patients. A 503B outsourcing facility registers with FDA, is subject to cGMP requirements, and can produce without patient-specific prescriptions, which is what office stock requires.
Does my supplier being licensed mean I can hold their product as stock?
Not by itself. The pharmacy’s licensure and your permission to hold office stock are separate questions, and both are answered state by state. A pharmacy lawfully shipping into one state tells you nothing about another.
What should I document?
Which state’s rule you are relying on, the date you checked it, the supplier’s category and licensure, the quantity basis, and the records that state requires you to keep. Arrangements drift as the footprint grows, and the documentation is what makes drift visible.
This is general information, not legal advice. Rules vary by state and change. Confirm your own facts with counsel.